What type of study is this?

This is a Human Clinical Trial study.

What question did this study set out to answer?

To evaluate the impact of iron chelation therapy on overall and progression-free survival in patients after stem cell transplantation for AML and MDS.

December 8, 2025BloodOpen Access

Impact on overall and progression-free survivals of iron chelation given 6 months after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia and myelodysplastic syndrom

View Full Paper

Ask AI

Bookmark

To evaluate the impact of iron chelation therapy on overall and progression-free survival in patients after stem cell transplantation for AML and MDS.
Prospective interventional study involving patients with AML/MDS undergoing allo-HSCT.
Iron chelation therapy with deferasirox initiated 6 months post-transplant in patients with ferritin levels above 1,000 µg/L.
Matched retrospective control group using propensity score matching to balance potential confounding variables.
Significant improvement in progression free survival (HR = 2.27, p = 0.039) with deferasirox treatment.
Overall survival showed a non-significant trend towards improvement (HR = 2.32, p = 0.065) in the multivariate model.
Median duration of treatment was 12.5 months; adverse events related to therapy were considered acceptable.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Interventional study shows iron chelation therapy with deferasirox improves progression free survival in AML and MDS patients, suggesting a valuable treatment approach.

Cite This Study

Huynh et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5b1 https://doi.org/10.1182/blood-2025-4297

View Full Paper

Ask AI

Bookmark

Implication

Interventional study shows iron chelation therapy with deferasirox improves progression free survival in AML and MDS patients, suggesting a valuable treatment approach.

Impact on overall and progression-free survivals of iron chelation given 6 months after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia and myelodysplastic syndrom

Key Points

Discussion

Implication

Cite This Study

Impact on overall and progression-free survivals of iron chelation given 6 months after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia and myelodysplastic syndrom

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider